RESUMO
Objective:To investigate effect and mechanism of mangiferin on regulation of M2-type macrophage polarization tar-geting MMP9 in pancreatic cancer.Methods:In vivo,therapeutic effect of mangiferin on pancreatic cancer was evaluated by drawing tumor growth curves and immunohistochemical staining.M2-type macrophages expression in pancreatic cancer was detected by immu-nofluorescence and ELISA.Effects of mangiferin on expression of MMP9 and downstream M2 macrophage polarization-related signaling pathways were detected by immunofluorescence,ELISA,Western blot and qRT-PCR.In vitro,MTT assay was utilized to detect effect of mangiferin on M2-type macrophage and therapeutic effect of mangiferin on pancreatic cancer.ELISA was used to detect effect of mangiferin on M2-type polarized macrophages.Effects of mangiferin on expression of MMP9 and its downstream signalling pathway were detected by immunofluorescence and Western blot.Results:Mangiferin had potential to inhibit growth of pancreatic cancer in mice pancreatic model,and could prevent expression of M2-polarized macrophages in pancreatic cancer in addition.At the same time,mangiferin could inhibit expression of MMP9 and downstream M2 macrophage polarization related signaling pathways in pancreatic cancer.Mangiferin inhibited proliferation of pancreatic cancer cells in a M2 type polarized macrophage-pancreas cancer cell co-culture model,inhibited macrophage M2 polarization,at the same time,expression of MMP9 and downstream M2 macrophage polarization related signaling pathway was inhibited.Conclusion:Mangiferin can inhibit macrophage M2 polarization by inhibiting MMP9 and its downstream signaling pathway,and play a role in pancreatic cancer therapy.
RESUMO
Objective: To investigate the expression levels of tumor markers squamous cell carcinoma antigen (SCC-Ag), carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA21-1) and D-dimer (D-D) of the patients with non-small cell lung cancer (NSCLC), and to elucidate its clinical value in the early diagnosis of NSCLC. Methods: A total of 200 patients with NSCLC (NSCLC group), 198 patients with benign lung disease (benign lung disease group) and 196 healthy subjects (control group) were selected and the levels of tumor markers and D-D were detected and compared between groups. The receiver operator characteristic curve (ROC) was drawn to analyze the diagnostic values of different tumor markers, D-D, and joint indicators in the patients with NSCLC. Results: The levels of tumor markers and D-D of the patients in NSCLC group were significantly higher than those in benign lung disease group and control group (P<0. 01). The level of CEA in lung adenocarcinoma was higher than that in lung squamous cell carcinoma (P=0. 005). The levels of SCC-Ag and CYFRA21-1 in lung squamous cell carcinoma were higher than those in lung adenocarcinoma (P=0. 008, P= 0. 004). The levels of tumor markers CKA. CYFRA21-1 and D-D of the patients with stage IE and IV NSCLC were significantly higher than those of the patients with stage I and II NSCLC (P<0. 05). The ROC curves showed that area under curve (AUC) of SCC-Ag was higher than other single indexes (AUC = 0.805); the sensitivity and specificity were 85.42% and 64.21%, respectively. The diagnostic efficacy of the joint indicators was better than that of each single index (AUC = 0.933); the sensitivity and specificity were 86.46% and 88.42%, respectively. Conclusion; Combined detection of tumor markers SCC-Ag, CEA, CYFRA21-1 and D-D can significantly increase the sensitivity and specificity of early diagnosis of NSCLC and has important significance in the early diagnosis of NSCLC.